ENDOLOGIX INC's ticker is and the CUSIP is 29266SAB2.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $2,651,000 | -53.1% | 8,250,000 | 0.0% | 0.00% | -75.0% |
| Q1 2019 | $5,648,000 | -3.6% | 8,250,000 | 0.0% | 0.01% | +60.0% |
| Q4 2018 | $5,858,000 | +2.4% | 8,250,000 | 0.0% | 0.01% | -28.6% |
| Q3 2018 | $5,723,000 | -24.1% | 8,250,000 | 0.0% | 0.01% | -36.4% |
| Q2 2018 | $7,540,000 | +6.3% | 8,250,000 | 0.0% | 0.01% | 0.0% |
| Q1 2018 | $7,095,000 | -5.2% | 8,250,000 | 0.0% | 0.01% | -8.3% |
| Q4 2017 | $7,482,000 | +4.8% | 8,250,000 | 0.0% | 0.01% | -47.8% |
| Q3 2017 | $7,136,000 | +19.2% | 8,250,000 | +17.9% | 0.02% | +15.0% |
| Q2 2017 | $5,989,000 | -13.4% | 7,000,000 | 0.0% | 0.02% | -13.0% |
| Q1 2017 | $6,917,000 | +13.1% | 7,000,000 | 0.0% | 0.02% | +4.5% |
| Q4 2016 | $6,116,000 | -23.0% | 7,000,000 | +16.7% | 0.02% | -24.1% |
| Q3 2016 | $7,946,000 | +1.8% | 6,000,000 | 0.0% | 0.03% | +3.6% |
| Q2 2016 | $7,804,000 | +36.6% | 6,000,000 | 0.0% | 0.03% | +33.3% |
| Q1 2016 | $5,715,000 | – | 6,000,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Context Capital Management, LLC | 3,500,000 | $3,793,000 | 5.91% |
| FNY Managed Accounts LLC | 500,000 | $542,190,000 | 2.68% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 30,000,000 | $32,548,000 | 1.32% |
| ZAZOVE ASSOCIATES LLC | 13,906,000 | $15,123,000 | 0.71% |
| DAFNA Capital Management LLC | 500,000 | $545,000 | 0.49% |
| SSI INVESTMENT MANAGEMENT LLC | 4,000,000 | $4,308,000 | 0.44% |
| CAMDEN ASSET MANAGEMENT L P /CA | 9,100,000 | $9,868,000 | 0.31% |
| LINDEN ADVISORS LP | 4,500,000 | $4,896,000 | 0.30% |
| WOLVERINE ASSET MANAGEMENT LLC | 11,000,000 | $11,949,000 | 0.26% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 300,000 | $327,000 | 0.05% |